Sclerostin antibody treatment improves fracture outcomes in a Type I diabetic mouse model.

@article{Yee2016SclerostinAT,
  title={Sclerostin antibody treatment improves fracture outcomes in a Type I diabetic mouse model.},
  author={Cristal S. Yee and Liqin Xie and Sarah J. Hatsell and Nicholas R. Hum and Deepa K. Murugesh and Aris N. Economides and Gabriela G. Loots and Nicole M.B. Collette},
  journal={Bone},
  year={2016},
  volume={82},
  pages={122-34}
}
Type 1 diabetes mellitus (T1DM) patients have osteopenia and impaired fracture healing due to decreased osteoblast activity. Further, no adequate treatments are currently available that can restore impaired healing in T1DM; hence a significant need exists to investigate new therapeutics for treatment of orthopedic complications. Sclerostin (SOST), a WNT antagonist, negatively regulates bone formation, and SostAb is a potent bone anabolic agent. To determine whether SOST antibody (SostAb… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Effect of Resveratrol on Critical-Sized Calvarial Defects of Diabetic Rats: Histometric and Gene Expression Analysis.

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons • 2017
View 13 Excerpts
Highly Influenced

Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes.

Proceedings of the National Academy of Sciences of the United States of America • 2017

Similar Papers

Loading similar papers…